INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | - | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr | ₹0.59 Cr |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | - |
| Mar2024 | ₹0.98 Cr |
| Mar2023 | ₹0.95 Cr |
| Mar2022 | ₹0.67 Cr |
| Mar2021 | ₹0.59 Cr |
How is Contingent Liabilities of INDO US BIOTECH Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | - | -100.00 | |
| Mar2024 | ₹0.98 Cr | 2.84 | |
| Mar2023 | ₹0.95 Cr | 42.64 | |
| Mar2022 | ₹0.67 Cr | 13.27 | |
| Mar2021 | ₹0.59 Cr | - | |
Compare Contingent Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹229.6 Cr | -1.1% | -8.6% | -55.4% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹12,880.2 Cr | 0.2% | -1% | -9.5% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,572.9 Cr | -2% | -8.9% | -0.7% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,189.1 Cr | 1.2% | 9% | -7.7% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,042.8 Cr | -3.6% | -1.3% | -29.8% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹397.1 Cr | -13.4% | -20% | -8.9% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -1.1% |
-8.6% |
-55.4% |
| SENSEX | -1.9% |
-2.2% |
7.4% |
You may also like the below Video Courses